How retroperitoneal lymph node dissection affects urination and sexual function
Voiding, Erectile and Ejaculatory Function After Retroperitoneal Lymph Node Dissection for Testicular Cancer
This project will see if retroperitoneal lymph node dissection (RPLND) for testicular cancer changes urination, ejaculation, erections, and quality of life in adult men.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | Jagiellonian University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Krakow, Malopolska) |
| Trial ID | NCT06954233 on ClinicalTrials.gov |
What this trial studies
This is a prospective observational study that follows adult men undergoing RPLND for testicular cancer with measurements taken before surgery and at scheduled visits up to six months after the operation. Participants complete validated patient-reported outcome measures for urinary symptoms, ejaculatory and erectile function, and quality of life, and undergo non-invasive tests including uroflowmetry and post-void residual ultrasound. The design pairs subjective questionnaires with objective flow and volume measurements to characterize the timing and magnitude of functional changes after RPLND. Data will be used to describe typical recovery patterns and identify factors associated with worse urinary or sexual outcomes.
Who should consider this trial
Good fit: Adult men with testicular cancer who are scheduled to undergo RPLND and can provide informed consent are ideal candidates for this study.
Not a fit: Men with a prior RPLND or those with irreversible preexisting urinary or sexual dysfunction unrelated to their current treatment are unlikely to benefit from this study's findings.
Why it matters
Potential benefit: If successful, the results could help clinicians predict, counsel about, and manage urinary and sexual side effects after RPLND, improving postoperative care and rehabilitation.
How similar studies have performed: Previous research has established that RPLND commonly affects ejaculation, but prospective, systematic data on effects on urine flow and erectile function are limited, making this partly novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult male with testicular cancer undergoing retroperitoneal lymph node dissection (RPLND) Exclusion Criteria: * History of RPLND * Lack of consent
Where this trial is running
Krakow, Malopolska
- Jagiellonian University Medical College — Krakow, Malopolska, Poland (Recruiting)
Study contacts
- Principal investigator: Anna K. Czech, M.D. — Jagiellonian University
- Study coordinator: Anna K. Czech, M.D., Ph.D.
- Email: aka.czech@uj.edu.pl
- Phone: +48124002500
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.